Healthcare Industry News: Animas Corp
News Release - June 16, 2010
HEALTHPOINT, Ltd. Announces New Vice President, Sales Brad AdamsFORT WORTH, Texas--(HSMN NewsFeed)--HEALTHPOINT, Ltd., a DFB Pharmaceuticals, Inc. company, has announced Brad Adams has joined the company as Vice President, Sales. Prior to Healthpoint, Mr. Adams achieved international experience in health care sales, marketing and business administration at several Johnson & Johnson affiliate companies.
“I am pleased to welcome Brad on board,” said Travis E. Baugh, President and Chief Operating Officer at Healthpoint. “His extensive exposure to and command of every aspect of healthcare business make him a tremendous addition to our team.”
Mr. Adams was most recently at Animas Corporation, an insulin delivery and glucose management systems company and Johnson & Johnson’s fastest growing medical device company, as VP worldwide sales and patient services.
Prior to Animas, Mr. Adams was VP worldwide sales for Johnson & Johnson affiliate Therakos, a photophoresis drug/device therapy company. He also served as Region Business Director for J&J’s Centocor business with $394 million in annual sales. Other Johnson & Johnson positions included Corporate Account Executive for the J&J Healthcare Systems group where he gained experience in healthcare systems and consulting.
Before joining Johnson & Johnson, Mr. Adams developed his healthcare administration skills as assistant administrator at Memorial Regional Medical Center in Richmond, Va.
As Vice President of Sales at Healthpoint, Mr. Adams’s responsibilities include leadership for the Wound Care and Specialty Sales forces, along with Sales Training and Sales Operations functions.
Mr. Adams counts his career as a commissioned officer in the United States Army as the foundation for his leadership acumen. He served as a platoon leader in South Korea, as an executive officer in Operation Desert Storm in Iraq, and completed a two-year tour of duty at Fort Hood in Killeen, Texas.
A graduate of Virginia Military Institute in Lexington, Va., with a degree in economics, Mr. Adams also earned a graduate degree in health administration from The Medical College of Virginia (Virginia Commonwealth University in Richmond, Va.).
Since 1992, HEALTHPOINT has been dedicated to innovative technologies for prevention and treatment of acute, chronic and burn-related wounds. The company is presently focused on research and development of novel biologics and pharmaceuticals intended to improve clinical and quality of life outcomes. Currently marketed products: Collagenase SANTYL® Ointment, OASIS® Wound Matrix, HYDROFERA BLUE® Bacteriostatic Wound Dressings, SURGICEPT® Waterless Surgical Hand Antiseptic and ULTRACEPTTM Antiseptic Handwash. HEALTHPOINT is also committed to advancing the care and treatment of wounds through support of industry leading continuing education from THE WOUND INSTITUTE®. To learn more about this comprehensive and award winning educational resource, please visit TheWoundInstitute.com®. HEALTHPOINT is a DFB Pharmaceuticals, Inc. affiliate company, and is based in Fort Worth, Texas. For more information, visit the HEALTHPOINT website: www.healthpoint.com.
OASIS is a registered trademark of Cook Biotech, Inc.
HYDROFERA BLUE is a registered trademark of Hydrofera, LLC.
SANTYL, SURGICEPT, THE WOUND INSTITUTE and THEWOUNDINSTITUTE.COM are registered trademarks of Healthpoint, Ltd.
ULTRACEPT is a trademark of Healthpoint, Ltd.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.